{
  "slug": "modulari-t",
  "name": "Modulari-T",
  "yc_id": 28205,
  "batch": "Winter 2023",
  "website": "https://modularit.bio",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:23:19.220083",
    "website": "https://modularit.bio",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 1181.08,
      "final_url": "https://modularit.bio/",
      "redirected": true,
      "checked_at": "2025-10-17T01:23:20.401166"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "modularit.bio",
      "error": "Whois command returned no output"
    },
    "social_links": {
      "twitter": null,
      "linkedin": null,
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": true,
      "content_security_policy": true,
      "x_frame_options": false,
      "x_content_type_options": false,
      "x_xss_protection": false,
      "referrer_policy": false,
      "security_score": 33,
      "server": "DPS/2.0.0+sha-6e30ec3"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:39:17.688093",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0",
    "model_used": "google/gemini-2.0-flash-001",
    "enriched_at": "2025-10-17T12:41:39.565995",
    "status": "success",
    "market_analysis": {
      "market_size": "very large",
      "market_stage": "growing",
      "key_trends": [
        "Advancements in cell and gene therapy",
        "Increased investment in personalized medicine",
        "Growing demand for effective cancer treatments"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Proprietary synthetic gene platform technology.",
      "differentiation": "Novel approach to reprogramming cells for targeted therapies, potentially offering greater precision and efficacy.",
      "competitive_advantages": [
        "Potentially more effective cancer treatment",
        "Platform technology applicable to multiple diseases"
      ],
      "competitive_vulnerabilities": [
        "Early stage, unproven technology",
        "Competition from established cell and gene therapy companies"
      ]
    },
    "business_model": {
      "revenue_model": "Licensing/Partnerships with pharmaceutical companies, direct therapeutic development.",
      "scalability": "high",
      "capital_intensity": "high"
    },
    "growth_assessment": {
      "growth_stage": "seed",
      "growth_indicators": [
        "Successful preclinical trials",
        "Strategic partnerships"
      ],
      "growth_bottlenecks": [
        "Regulatory hurdles",
        "Securing funding for clinical trials"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "medium",
      "overall_risk_score": 7,
      "key_risks": [
        "Clinical trial failures",
        "Competition from alternative therapies",
        "Manufacturing challenges"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Novel platform technology",
        "Large market opportunity",
        "Potential for high impact on human health"
      ],
      "concerns": [
        "High capital requirements",
        "Long development timelines"
      ],
      "exit_potential": "IPO/acquisition",
      "comparable_companies": [
        "CRISPR Therapeutics",
        "bluebird bio"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Secure seed funding",
        "Demonstrate efficacy in preclinical models",
        "Build a strong team with expertise in cell and gene therapy"
      ],
      "expansion_opportunities": [
        "Expand platform to other disease areas",
        "Develop strategic partnerships with pharmaceutical companies"
      ]
    },
    "tokens_used": {
      "prompt": 704,
      "completion": 593,
      "total": 1297,
      "estimated_cost": 0.000231
    }
  },
  "phase8_complete": true
}